Owner Investor / Financier Operator Developer Technology / equipment supplier
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical company based in Japan. Founded in 1781, the company discovers, develops, manufactures, and markets prescription medicines and vaccines. Its core therapeutic areas include gastroenterology and inflammation, oncology, neuroscience, rare genetic and hematology diseases, plasma-derived therapies, and vaccines.
Takeda operates an international R&D and manufacturing network that spans small‑molecule and biologic modalities. Capabilities include medicinal chemistry, process and scale-up chemistry, biologics development and production, plasma fractionation, and formulation and fill‑finish. The company produces active pharmaceutical ingredients (APIs) and finished dosage forms for global markets, supplying healthcare systems in numerous countries. Its activities intersect with the broader chemical value chain through API synthesis, process development, quality control, and compliance with global cGMP and regulatory standards.
Also known as 武田薬品, Takeda Pharmaceuticals, 武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha, Takeda Yakuhin Kōgyō Kabushiki Kaisha and 1 more.
chemXplore tracks 6 projects involving Takeda, of which 2 are active.
Besides these 2, the record holds 4 completed projects.
Closest to start-up first.
The 4 that are completed, on hold or cancelled are in the record. See all 6 in chemXplore
The oral OX2R agonist is a Schedule IV controlled substance and will be dispensed through Accredo Specialty Pharmacy.
Revenue +8.4% AER; core operating profit +11.2% AER; ORZEYFUL approved in US/Japan/China; MIMRYLO launched in US; zasocitinib accepted for FDA Priority Review; FY outlook raised for FX.
Phase 3 G‑HOPE‑001 met dual endpoints in CLDN18.2‑positive advanced G/GEJA—median OS 10.2 vs 6.9 months and PFS 7.1 vs 3.1 months versus physician’s choice.
Treating to corticosteroid-free disease clearance with vedolizumab lengthened time to first ulcerative colitis complication and cut complication risk by about 70%.
First-in-class oral OX2R agonist now available; U.S. launch due next month pending DEA scheduling; Phase 3 showed significant improvements across NT1 symptoms with a consistent safety profile.
Pivotal IgGNITE results in patients ≥16 show similar IgG exposure to HYQVIA with 50% less infusion volume, shorter administration times, comparable safety and planned FY2026 regulatory filings.
FDA granted priority review to an oral TYK2 inhibitor after Phase 3 data from nearly 3,000 patients showed rapid, durable skin clearance; PDUFA target Q1 2027.
First-in-class hepcidin mimetic approved for adult PV erythrocytosis; Phase 3 VERIFY showed hematocrit control, reduced phlebotomy and improved fatigue.
